Recruiting studies: Chronic Myelomonocytic Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogen
Phase 1/Phase 2 · 6 location(s) · Heinrich-Heine University, Duesseldorf · NCT05807932 Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leuk
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04140487 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT03314974 Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)
Phase N/A · 1 location(s) · Centre Hospitalier Universitaire de Nice · NCT03280888 Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant
Phase 1/Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT06928662 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Phase N/A · 1 location(s) · Barbara Ann Karmanos Cancer Institute · NCT00935090 A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Lo
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04239157 (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Phase 2 · 42 location(s) · Cogent Biosciences, Inc. · NCT04996875 A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Phase 1/Phase 2 · 19 location(s) · Therapeutic Advances in Childhood Leukemia Consortium · NCT05849662 A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Phase 1 · 11 location(s) · Crossbow Therapeutics, Inc. · NCT06994676 Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572 Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (
Phase 2 · 1 location(s) · Hannah Choe, MD · NCT07249346 Two Step Haplo With Radiation Conditioning
Phase 2 · 1 location(s) · Thomas Jefferson University · NCT05031897 A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetocla
Phase 2/Phase 3 · 71 location(s) · Taiho Oncology, Inc. · NCT04256317 A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS
Phase 1 · 19 location(s) · Children's Oncology Group · NCT06247787 A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05365035 MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
Phase 2 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT05735717 Combining Active and Passive DNA Hypomethylation
Phase 2 · 10 location(s) · Kirsten Grønbæk · NCT03999723 Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML
Phase 1/Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05584761 Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hem
Phase 2 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07046078 CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relap
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT04375631 The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia T
Phase 1/Phase 2 · 183 location(s) · PedAL BCU, LLC · NCT04726241 Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove
EARLY_Phase 1 · 1 location(s) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · NCT07071155 Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Phase 2 · 3 location(s) · Montefiore Medical Center · NCT05184842 Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
Phase N/A · 1 location(s) · Shanghai General Hospital, Shanghai Jiao Tong University Sch · NCT06111612 Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations
Phase N/A · 19 location(s) · Blueprint Medicines Corporation · NCT07143669 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting C
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05092451 Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
Phase 2 · 1 location(s) · University of Florida · NCT05800210 Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Phase 1 · 6 location(s) · Epigenetix, Inc. · NCT05488548 Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.